Neurocrine Biosciences, Inc.
NBIXHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePart of the healthcare sector, Neurocrine Biosciences, Inc. (NBIX) is listed under Drug Manufacturers - Specialty & Generic. Valued at $15.82B, NBIX is a large-cap name in its sector. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody.
Market Cap
$15.82B
Beta
0.38
P/E (TTM)
22.79
P/E (Fwd)
13.00
EPS (TTM)
$6.83
EPS (Fwd)
$11.97
ROE
22.1%
ROA
11.7%
Cash
$389.8M
Total Debt
$461.6M
Free CF
$638.2M
52W Change
8.0%
Annual Financials
Cash vs Debt
Where NBIX stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, NBIX finished 3.70% above its 150-day moving average ($148.53) and 4.58% above its 200-day moving average ($147.29). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NBIX overbought or oversold?
At the September 1, 2026 close, NBIX's RSI(14) was 34.7, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $389.8M in cash, though total debt stands at $461.6M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $638.2M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 22.1% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 11.7% further supports the picture of efficient asset utilization. Revenue has grown from $1.49B (2022) to $2.86B (2025), reflecting a 92% increase over the period.
With a beta below 0.7, Neurocrine Biosciences, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Neurocrine Biosciences, Inc.'s trajectory.